Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Cannabinoids Reveal Separate Controls for Whisking Amplitude and Timing in Rats

View through CrossRef
Whisking is controlled by multiple, possibly functionally segregated, motor sensory-motor loops. While testing for effects of endocannabinoids on whisking, we uncovered the first known functional segregation of channels controlling whisking amplitude and timing. Channels controlling amplitude, but not timing, were modulated by cannabinoid receptor type 1 (CB1R). Systemic administration of CB1R agonist Δ9-tetrahydrocannabinol (Δ9-THC) reduced whisking spectral power across all tested doses (1.25–5 mg/kg), whereas whisking frequency was affected at only very high doses (5 mg/kg). Concomitantly, whisking amplitude and velocity were significantly reduced in a dose-dependent manner (25–43 and 26–50%, respectively), whereas cycle duration and bilateral synchrony were hardly affected (3–16 and 3–9%, respectively). Preadministration of CB1R antagonist SR141716A blocked Δ9-THC–induced kinematic alterations of whisking, and when administered alone, increased whisking amplitude and velocity but affected neither cycle duration nor synchrony. These findings indicate that whisking amplitude and timing are controlled by separate channels and that endocannabinoids modulate amplitude control channels.
Title: Cannabinoids Reveal Separate Controls for Whisking Amplitude and Timing in Rats
Description:
Whisking is controlled by multiple, possibly functionally segregated, motor sensory-motor loops.
While testing for effects of endocannabinoids on whisking, we uncovered the first known functional segregation of channels controlling whisking amplitude and timing.
Channels controlling amplitude, but not timing, were modulated by cannabinoid receptor type 1 (CB1R).
Systemic administration of CB1R agonist Δ9-tetrahydrocannabinol (Δ9-THC) reduced whisking spectral power across all tested doses (1.
25–5 mg/kg), whereas whisking frequency was affected at only very high doses (5 mg/kg).
Concomitantly, whisking amplitude and velocity were significantly reduced in a dose-dependent manner (25–43 and 26–50%, respectively), whereas cycle duration and bilateral synchrony were hardly affected (3–16 and 3–9%, respectively).
Preadministration of CB1R antagonist SR141716A blocked Δ9-THC–induced kinematic alterations of whisking, and when administered alone, increased whisking amplitude and velocity but affected neither cycle duration nor synchrony.
These findings indicate that whisking amplitude and timing are controlled by separate channels and that endocannabinoids modulate amplitude control channels.

Related Results

Inhibitory Effects of Cannabinoids on Acetylcholinesterase and Butyrylcholinesterase Enzyme Activities
Inhibitory Effects of Cannabinoids on Acetylcholinesterase and Butyrylcholinesterase Enzyme Activities
<b><i>Introduction:</i></b> Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are two cholinergic enzymes catalyzing the reaction of cleaving ace...
Neurocognitive Changes in Adolescents with Synthetic Cannabinoids Use Disorder
Neurocognitive Changes in Adolescents with Synthetic Cannabinoids Use Disorder
Abstract Background Synthetic cannabinoids are one of the most used novel psychoactive substances among adolescents with eminent...
Therapeutic Use of Cannabinoids: Clinical Overview and Recent Updates
Therapeutic Use of Cannabinoids: Clinical Overview and Recent Updates
Cannabinoids, regardless of their structure or origin, refer to chemical substances that act on cannabinoid receptors and produce pharmacological effects similar to Δ9-tetrahydroca...
e0157 RNA interference targeting ACE and AT1R gene reduced blood pressure and improved myocardial remodelling in SHR
e0157 RNA interference targeting ACE and AT1R gene reduced blood pressure and improved myocardial remodelling in SHR
Introduction Angiotensin-converting enzyme (ACE) and angiotensin II (Ang II) Type 1 receptor (ATlR) have been shown to play an important role in the pathogenesis ...
Cannabinoids in the Treatment of Epilepsy: A Review
Cannabinoids in the Treatment of Epilepsy: A Review
Cannabinoids have been studied for their role in the treatment of epilepsy for many years. The U.S. Food and Drug Administration (FDA) approved them for the treatment of some refra...
Cannabinoids for the treatment of autoimmune and inflammatory skin diseases: A systematic review
Cannabinoids for the treatment of autoimmune and inflammatory skin diseases: A systematic review
AbstractIn recent years, the medical use of cannabinoids has attracted growing attention worldwide. In particular, anti‐inflammatory properties of cannabinoids led to their emergen...
Cannabinoids as Key Regulators of Inflammasome Signaling: A Current Perspective
Cannabinoids as Key Regulators of Inflammasome Signaling: A Current Perspective
Inflammasomes are cytoplasmic inflammatory signaling protein complexes that detect microbial materials, sterile inflammatory insults, and certain host-derived elements. Inflammasom...

Back to Top